title: A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients.
abstract: Thirty patients with chemotherapy-naïve advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.
authors.affiliation: University Hospital Vrije Universiteit Amsterdam, The Netherlands. G.Giaccone@azvu.nl
authors.forename: G
authors.initials: G
authors.lastname: Giaccone
authors.forename: E F
authors.initials: EF
authors.lastname: Smit
authors.forename: J P
authors.initials: JP
authors.lastname: van Meerbeeck
authors.forename: T
authors.initials: T
authors.lastname: Splinter
authors.forename: R P
authors.initials: RP
authors.lastname: Golding
authors.forename: H M
authors.initials: HM
authors.lastname: Pinedo
authors.forename: D
authors.initials: D
authors.lastname: Laan
authors.forename: H
authors.initials: H
authors.lastname: van Tinteren
authors.forename: P E
authors.initials: PE
authors.lastname: Postmus
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine